Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.77 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.60 |
| ▸ | TNKS | O95271 | 1/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.60 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.60 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.60 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.60 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11889787 | 0.91 | PARP1 (0.77) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630164 | 0.87 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL631457 | 0.87 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL631456 | 0.87 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL31589797 | 0.86 | PARP1 (0.68) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL24984791 | 0.84 | PARP1 (0.75) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630641 | 0.84 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630711 | 0.84 | PARP1 (0.80) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630122 | 0.84 | PARP1 (0.80) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL23869629 | 0.84 | PARP1 (0.75) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD (IL) | 2021-01-14 | — | — | US | disclosed |
| WO-2019159168-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD. (IL) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | CNR1, GLRA1, GLRA3 | PARP1 1207/4885PARP2 2815/4885TNKS 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.